#1 Clinical Trials Search in Europe

Elasomeran

This article explores the use of Elasomeran, a key component in COVID-19 mRNA vaccines, in various clinical trials. These studies aim to assess the vaccine’s effectiveness, immune responses, and potential applications in different populations. The trials cover topics such as comparing high-dose and standard-dose influenza vaccines, investigating immune responses in COVID-19 recovered patients, and evaluating long-term immunity after vaccination.

Table of Contents

What is ELASOMERAN?

ELASOMERAN is an active ingredient used in COVID-19 vaccines, specifically in the Spikevax vaccine developed by Moderna[1]. It is a type of medicine known as an mRNA (messenger RNA) vaccine. ELASOMERAN is also known by several other names, including:

  • mRNA-1273
  • CX-024414
  • COVID-19 mRNA vaccine Moderna (CX-024414)

These names are synonyms for ELASOMERAN, which means they all refer to the same substance[2].

How does ELASOMERAN work?

ELASOMERAN works by providing your body with instructions to produce a specific protein found on the surface of the SARS-CoV-2 virus, which causes COVID-19. This protein is called the spike protein. Here’s how it works:

  1. The vaccine contains mRNA, which is like a blueprint for making the spike protein.
  2. When injected, the mRNA enters your cells.
  3. Your cells read the mRNA instructions and produce copies of the spike protein.
  4. Your immune system recognizes these spike proteins as foreign and creates antibodies against them.
  5. If you’re later exposed to the real SARS-CoV-2 virus, your immune system is prepared to fight it off quickly.

This innovative approach allows your body to develop immunity without being exposed to the actual virus[1].

Medical Conditions Treated

ELASOMERAN is primarily used for the prevention of COVID-19 infection. It’s important to note that it’s a preventive measure, not a treatment for active COVID-19 infections. The vaccine is designed to help your immune system recognize and fight off the SARS-CoV-2 virus if you’re exposed to it in the future[1][3].

Administration and Dosage

ELASOMERAN is administered as an intramuscular injection, typically in the upper arm. The dosage can vary depending on the specific formulation and vaccination schedule. For example:

  • Some formulations use 50 micrograms per dose[3].
  • Others may use up to 100 micrograms per dose[2].
  • The vaccine may be given as a single dose or as part of a series of injections, depending on the specific vaccination protocol and your individual circumstances.

Always follow the vaccination schedule recommended by your healthcare provider or local health authorities.

Effectiveness and Ongoing Research

Research on ELASOMERAN and its effectiveness is ongoing. Current studies are investigating various aspects of the vaccine, including:

  • The effectiveness of different vaccine formulations and dosing schedules[3].
  • How long immunity lasts after vaccination[3].
  • The vaccine’s effectiveness against different virus variants[3].
  • The impact of previous COVID-19 infections on vaccine responses[3].
  • The relationship between immune responses and clinical protection[3].

These studies help scientists and healthcare professionals understand how to best use the vaccine to protect people from COVID-19.

Safety and Side Effects

Like all vaccines, ELASOMERAN can cause side effects, although not everyone experiences them. Common side effects may include:

  • Pain or swelling at the injection site
  • Fatigue
  • Headache
  • Muscle pain
  • Chills
  • Fever

These side effects are usually mild and go away within a few days. Serious side effects are rare but can occur. If you experience any severe or persistent side effects after vaccination, contact your healthcare provider immediately.

Patient Considerations

If you’re considering or scheduled to receive a vaccine containing ELASOMERAN, keep the following in mind:

  • Inform your healthcare provider about any allergies or medical conditions you have.
  • Tell them if you’ve had COVID-19 in the past or if you’ve received other COVID-19 vaccines.
  • Follow all instructions regarding dosing schedules and any recommended precautions after vaccination.
  • Continue following public health guidelines even after vaccination, as recommended by your local health authorities.

Remember, vaccination is an important tool in preventing the spread of COVID-19, but it works best when combined with other preventive measures like hand washing, mask-wearing when recommended, and social distancing as appropriate.

Aspect Details
Main Objectives Evaluate vaccine effectiveness, assess immune responses, compare vaccine formulations and dosing schedules
Study Populations Older adults (65+ years), COVID-19 recovered patients, various age groups and risk categories
Key Endpoints Hospitalization rates, antibody levels, neutralizing antibody titers, cellular immune responses
Administration Intramuscular injection, varying dosages and schedules
Vaccine Formulations Different Elasomeran-based products, including bivalent vaccines targeting multiple variants
Follow-up Duration Ranging from several months to over a year, depending on the study
Additional Focuses Impact of prior COVID-19 infection, combination with influenza vaccination, response to different virus variants

FAQ

  • What is Elasomeran? Elasomeran is an active substance used in COVID-19 mRNA vaccines. It is a single-stranded, 5'-capped messenger RNA (mRNA) that encodes the viral spike (S) protein of SARS-CoV-2, the virus that causes COVID-19.
  • What are the main objectives of the clinical trials involving Elasomeran? The main objectives include evaluating vaccine effectiveness, assessing immune responses over time, comparing different vaccine formulations and dosing schedules, and investigating the impact of vaccination on various populations, including older adults and those who have recovered from COVID-19.
  • How is Elasomeran administered in these trials? Elasomeran is typically administered through intramuscular injection. The dosage and frequency may vary depending on the specific trial and vaccine formulation being studied.
  • What are some of the endpoints being measured in these trials? Endpoints include hospitalization rates for influenza or pneumonia, antibody levels, neutralizing antibody titers, cellular immune responses, and the proportion of subjects with antibody levels above target thresholds against prevailing virus variants.
  • Are there any specific populations being studied in these Elasomeran trials? Yes, the trials focus on various populations, including older adults (65 years and above), individuals who have recovered from COVID-19, and people with different vaccination statuses. Some studies also look at different age groups and those with underlying health conditions.

Ongoing Clinical Trials on Elasomeran

  • Study on Immune Response in COVID-19 Recovered Patients Treated with Monoclonal Antibodies: Effects of Revaccination with Elasomeran, Tozinameran, and Cilgavimab

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Italy

  • A Study Testing mRNA-1273 Vaccine Safety and Effectiveness Against Severe COVID-19 in Adults Aged 50-64 Years Without Risk Factors

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Denmark

  • Study on Immune Responses to COVID-19 Vaccines: Raxtozinameran, Bretovameran, and Drug Combination for COVID-19 Patients

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study Comparing High-Dose vs. Standard-Dose Influenza Vaccine for Preventing Flu in Older Adults

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Elasomeran: An active substance used in COVID-19 mRNA vaccines, consisting of a single-stranded, 5'-capped messenger RNA that encodes the viral spike protein of SARS-CoV-2.
  • mRNA: Messenger RNA, a type of genetic material that carries instructions for making proteins in cells. In vaccines, it's used to instruct cells to produce specific viral proteins to trigger an immune response.
  • Spike (S) protein: A protein on the surface of the SARS-CoV-2 virus that allows it to enter human cells. It's a key target for vaccines and antibodies.
  • Humoral immune response: The part of the immune system that involves antibodies produced by B cells to fight off pathogens.
  • Cellular immune response: The part of the immune system that involves T cells, which can directly attack infected cells and help coordinate other immune responses.
  • Neutralizing antibodies: Antibodies that can bind to a virus and prevent it from infecting cells or replicating.
  • Monoclonal antibodies (MAbs): Laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attack specific parts of a virus.
  • Revaccination: The process of administering additional doses of a vaccine after the initial vaccination series to boost or maintain immunity.
  • Seropositive: Having a positive result in a blood test for a specific antibody, indicating previous exposure to a particular antigen or pathogen.
  • Immunocompromised: Having a weakened immune system, which can be due to certain diseases or medical treatments, making a person more susceptible to infections.

References

  1. http://clinicaltrials.eu/trial-id/2022-500657-17-00
  2. http://clinicaltrials.eu/trial/study-on-immune-response-in-covid-19-recovered-patients-treated-with-monoclonal-antibodies-effects-of-revaccination-with-elasomeran-tozinameran-and-cilgavimab/
  3. http://clinicaltrials.eu/trial-id/2024-517357-27-00